Influence of hypertension and global or abdominal obesity on left ventricular hypertrophy: A cross‐sectional study

Abstract

AbstractAlthough hypertension and obesity are both risk factors for left ventricular hypertrophy (LVH), the extent of their impact on LVH in the general population is still unclear, and the predictive value of obesity indicators for LVH remains to be elucidated. In this study, obesity‐related indicators, including waist circumference (WC), waist‐height ratio (WHTR), and waist‐hip ratio (WHR), were used to define abdominal obesity (AO), whereas body mass index (BMI) was used to measure general obesity (GO). The effects of hypertension and obesity on LVH were estimated using logistic regression analysis, as was the relative risk of LVH based on the presence of obesity, hypertension, or both. Subgroup analyses were performed based on sex and age. Of the 9134 participants (≥35 years old), 915 (10.0%) developed LVH. After adjusting for covariates, the odds ratios (95% confidence intervals) for LVH were 3.94 (3.27–4.75) in patients with hypertension, 1.90 (1.60–2.26) in those with GO, and 1.45 (1.25–1.69), 1.69 (1.43–2.00), and 1.54 (1.33–4.75) in individuals with AO defined based on WC, WHTR, and WHR, respectively. Analysis by sex showed similar values in women, but AO based on WC and WHR were not significantly associated with LVH in men. Further, after adjusting for potential confounding factors, concomitant hypertension and obesity had an increased risk of developing LVH in all age ranges, particularly in patients aged 35–45 years (risk increased 14.14‐fold, 10.84‐fold, 7.97‐fold, and 9.95‐fold for BMI‐based GO and WC‐, WHTR‐, and WHR‐based AO, respectively), and in both men and women but particularly in men (risk increased 7.71‐fold, 4.67‐fold, 5.83‐fold, and 5.58‐fold, respectively). In summary, all obesity indicators (BMI, WC, WHTR, and WHR) had predictive value for LVH in women; however, only BMI and WHTR should be considered for men. Furthermore, monitoring for the occurrence and progression of LVH is imperative for rural Chinese patients with concomitant hypertension and obesity, especially men and those aged 35–45 years.